BPC-157

Research Peptide

Also known as: Body Protection Compound 157 · Body Protective Compound · Pentadecapeptide BPC-157 · BPC 15 · BPC157 · PL 14736 · Bepecin

Animal Only

BPC-157 has a substantial preclinical literature (over 100 rodent studies, three decades). A registered trial that would have produced pharmacokinetic data was cancelled without publication. Calibrated assessment: mechanistically plausible, preclinically robust, unvalidated beyond animal and in vitro models.

For laboratory research use only. Not for human or animal consumption.

Evidence Tier

Animal Only

Mol. Weight

1419.55 Da

Last Reviewed

Apr 17, 2026

Claimed benefits by evidence tier

Column header colour matches the tier

Animal Only6

Tendon & ligament healing
Muscle injury recovery
Gut healing / ulcer repair
Nerve regeneration / traumatic brain injury
Anxiety and depression
Topical skin and wound healing

Anecdotal1

Leaky gut / SIBO

Unsupported1

Anti-aging / longevity

About this peptide

Plain English

BPC stands for "Body Protection Compound." It is a 15-amino-acid chain that researchers isolated from a larger protein found in human stomach juice. The idea is that the stomach produces this fragment as part of how it protects itself from its own acid, and that this protective effect might carry over to other tissues. Most of the attention BPC-157 gets online comes from rat and mouse studies showing faster healing of tendons, muscle, gut lining, and blood vessels. The evidence base is limited to animal and in vitro studies.

Technical

BPC-157 is a synthetic pentadecapeptide corresponding to residues 14–28 of Body Protection Compound, an unidentified larger protein isolated from human gastric juice. The sequence is stable in human gastric juice and resistant to enzymatic degradation, unusual for a peptide of its size. Proposed activity centers on VEGFR2 upregulation driving angiogenesis, NO-system modulation contributing to vasodilation and cytoprotection, and growth hormone receptor upregulation in tendon fibroblasts. The vast majority of the mechanistic data derives from a single Croatian research group (Sikirić et al.) across rodent models; pharmacokinetic data is limited to animal studies.

Mechanism of action

VEGFR2 / angiogenesis

Upregulates VEGFR2 signaling, accelerating new blood vessel formation at injury sites in animal models.

PMC PMC

Nitric oxide system

Modulates NO production; rodent studies describe countering both NO-blockade and excessive NO states, contributing to vasodilation and cytoprotection.

PMC

Growth hormone receptor

Increases GHR expression in tendon fibroblasts in preclinical models, cited as a possible explanation for tendon-healing observations.

PMC

Inflammatory cytokines

Reduces TNF-α and IL-6 in animal models of tissue injury.

PMC PMC

Neurotransmitter systems (CNS)

Interacts with dopaminergic, serotonergic, GABAergic, adrenergic, and cholinergic systems in rodent CNS studies, basis for speculative mood and neuroprotection claims.

PMC

Nearly all mechanistic data for BPC-157 comes from rats, mice, and isolated cells, overwhelmingly from one research group (Sikirić et al., Zagreb). Pharmacokinetic data is limited to animal studies. A registered trial (NCT02637284) that would have produced further data was cancelled and never published, without public explanation.

Key studies

Independence warning: most research for this peptide originates from a single research group. Replication by independent groups is limited.

Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (2025)

Vasireddi N, Hahamyan H, Salata MJ, et al. · American Journal of Sports Medicine / HSS Journal

Participants: Systematic review of literature (not patient-level)
Methodology: PRISMA systematic review. PubMed, Cochrane, Embase searched from inception to June 2024. 544 articles screened by two blinded reviewers.
Result: 36 studies met inclusion: 35 preclinical (animal/cell), 1 clinical (the Lee 2021 knee pain case series). Authors conclude BPC-157 should not be recommended for clinical use in musculoskeletal medicine until well-designed human trials are conducted.

Honest read
Independent research group with no financial conflict. Robust methodology. The conclusion reflects the actual state of the evidence. This is the most defensible summary position available.

PMC

Research timeline

1991
BPC first isolated from human gastric juice (Sikirić group, Zagreb).
PMC
2015
A trial registered under NCT02637284 (sponsor PharmaCotherapia, registered as "Bepecin") was launched.
NCT02637284
2016
Phase I trial submission cancelled. No results published. No public explanation.
NCT02637284
2021
First published case series involving intra-articular injection for knee pain, n=16 (Lee and Padgett). Single group, conflict of interest noted.
Source
2022
Rat and dog pharmacokinetic study published; rodent half-life ~5–15 minutes (He et al.).
PMC
2022
BPC-157 added to a major international anti-doping prohibited list under the Non-Approved Substances category.
WADA Source
2023
BPC-157 moved to Category 2 on the 503A bulks list, citing potential safety risks.
FDA
2024
Small uncontrolled case series on interstitial cystitis published, n=12 (Lee, Walker and Ayadi). Single group, no control arm.
PubMed
2025
Very small IV tolerability pilot published, n=2 (Lee and Burgess). Uncontrolled, insufficient to establish a safety profile.
PMID:40131143
2025
Systematic review for orthopaedic use (Vasireddi et al.): 544 articles screened, 35 qualifying preclinical studies and 1 very small uncontrolled case series. Authors conclude evidence is insufficient to support use.
PMC
2026
Regulatory advisory committee review of BPC-157 (free base and acetate) underway for a specific indication. Public docket FDA-2025-N-6895, comments close July 22, 2026.
FDA-2025-N-6895

What we don't know

Pharmacokinetics, half-life, distribution, and oral bioavailability are established only in animal models.
Long-term safety data is absent; existing studies involve very short exposure windows.
Cancer risk, BPC-157 upregulates angiogenesis (VEGFR2), the same pathway tumors exploit. Theoretical concern flagged in multiple reviews. No long-term cohort data exists to detect or rule out such effects.
Oral efficacy, claimed in marketing, has been demonstrated only in vitro and in rodent models.
Optimal research parameters (dose, route, frequency) all extrapolate from rat studies.
Replication, nearly all efficacy claims derive from a single research group (Sikirić et al.) or from a single small clinical group (Lee et al.).

Stability & handling

Lyophilized shelf life: Approximately 2 years at -20°C
Lyophilized storage: Freeze at -20°C or below; protect from light
Reconstitution diluents: Bacteriostatic water (preferred), Sterile 0.9% sodium chloride
Reconstituted (refrigerated): Approximately 30 days at 2–8°C
Reconstituted (room temp): Approximately 7 days at room temperature
OK to refreeze: No
Light sensitive: Yes, protect from light

Stability figures are based on common research-lab handling conventions, not peptide-specific stability-indicating studies.

Frequently asked questions

Why is BPC-157 on the Category 2 bulks list?

BPC-157 was moved to Category 2 of the 503A bulks list in September 2023, citing potential significant safety risks including immunogenicity concerns and insufficient safety data. Advocacy groups (Alliance for Pharmacy Compounding, Evexias) have contested the decision, arguing the underlying safety data was never publicly disclosed. A regulatory advisory committee review is underway in 2026 for a specific indication.

What should I look for on a BPC-157 COA?

At minimum, a batch-specific certificate with HPLC purity, mass spectrometry confirmation of the correct molecular weight (1419.55 Da), and peptide content (not only stated purity, the two are different because acetate or TFA salt weight is often counted toward mass). Endotoxin testing is relevant for any injectable-intended peptide. ClearBatch's vendor pages show which vendors publish each of these signals for their BPC-157 batches.

What is "Pentadeca Arginate" and how does it relate to BPC-157?

Pentadeca Arginate (PDA, also called BPC-157 Arginate) is a salt form rebranded and marketed after BPC-157 was moved to Category 2. Vendors market it as a compliant alternative. The pharmacology is essentially the same peptide with a different counterion; the regulatory claim is contested, and the peptide itself has no independent preclinical or controlled research beyond what exists for BPC-157. Treat marketing claims about PDA with the same skepticism as BPC-157.

Last researched: Apr 17, 2026

Get the ClearBatch Report

Bi-weekly: new peptide reference profiles, third-party-tested batches, and sourcing updates.

Two emails a month. Unsubscribe anytime.